Pooled data analysis from three phase I/II larotrectinib clinical trials (NCT02576431, NCT02122913, and NCT02637687) included 29 patients with TRK-fusion-positive thyroid cancer. Here, NTRK1 is linked to thyroid gland carcinoma.